Revvity
Supplies research tools, scientific software, and clinical diagnostics from discovery through screening.
Something off on this page? Send us feedback.
Profile
Supplies reagents, instruments, scientific software, laboratory services, and clinical testing workflows across Life Sciences and Diagnostics. Revenue is split roughly evenly between the segments, spanning research tools on one side and immunodiagnostics, reproductive health, and genomics on the other.
Operates through Life Sciences and Diagnostics. Life Sciences spans BioLegend reagents, assay technologies, imaging and automation instruments, Revvity Signals scientific software, and multi-omics services used in drug discovery and development.
Diagnostics provides reproductive-health and newborn-screening platforms, genomic testing, cord-blood banking through ViaCord, and EUROIMMUN and T-SPOT immunodiagnostics. Across both segments, the model pairs specialized consumables with instruments, software, laboratory services, and licensing for pharmaceutical and biotechnology companies, clinical laboratories, universities, and government customers.
Products reach customers through specialized sales teams and distributors across more than 160 countries. Clinical assays and screening systems depend on country-specific approvals and quality compliance, while some critical inputs come from limited or single suppliers. An agreed sale of the China immunodiagnostics business remains subject to closing and regulatory approval.
Company facts
Categories
Key statistics
Year to date +31.2% · Average volume (30d) 1.5M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 6, 2026 | Evercore ISI | Reiterate | Outperform | $118 | $125 | |
| Jun 26, 2026 | Bernstein | Target | $130 | $115 | ||
| May 6, 2026 | Stifel Nicolaus | Target | $110 | $100 | ||
| May 6, 2026 | Robert W. Baird | Target | $125 | $117 | ||
| May 4, 2026 | Robert W. Baird | Target | $129 | $125 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $1.21 | $1.41 | +16.5% | $703.0M | $711.0M | +1.1% | −3.32% |
| May 5, 2026Q1 FY26 | $1.02 | $1.06 | +3.9% | $704.1M | $711.1M | +1.0% | +7.36% |
| Feb 2, 2026Q4 FY25 | $1.57 | $1.70 | +8.3% | $764.9M | $772.1M | +0.9% | −5.57% |
| Oct 27, 2025Q3 FY25 | $1.14 | $1.18 | +3.5% | $699.4M | $698.9M | −0.1% | −0.73% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $664.8M | $720.3M | $698.9M | $772.1M | $711.1M | $729.7M | |
| Gross profit | $375.5M | $392.6M | $374.6M | $338.1M | $387.7M | $416.9M | |
| Operating income | $72.2M | $90.8M | $81.9M | $111.7M | $75.9M | $89.3M | |
| Net income | $42.2M | $55.2M | $46.7M | $98.4M | $40.7M | $51.8M | |
| Diluted EPS | $0.34 | $0.47 | $0.40 | $0.87 | $0.36 | $0.47 | |
| Gross margin | 56.5% | 54.5% | 53.6% | 43.8% | 54.5% | 57.1% | |
| Operating margin | 10.9% | 12.6% | 11.7% | 14.5% | 10.7% | 12.2% |
Fiscal years (4-quarter sums)FY21 $4.43B · FY22 $3.31B · FY23 $2.75B · FY24 $2.76B · FY25 $2.86B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jul 5, 2026Cash & short-term investments $1.02B · Total debt $3.34B · Total assets $12.05B · Shareholders' equity $7.23B
Dividends
Raised for 41 straight years. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 17, 2026 | Jul 17 | Aug 7 | $0.07 | |
| Apr 17, 2026 | Apr 17 | May 8 | $0.07 | |
| Jan 16, 2026 | Jan 16 | Feb 6 | $0.07 | |
| Oct 17, 2025 | Oct 17 | Nov 7 | $0.07 | |
| Jul 18, 2025 | Jul 18 | Aug 8 | $0.07 | |
| Apr 17, 2025 | Apr 18 | May 9 | $0.07 | |
| Jan 17, 2025 | Jan 17 | Feb 7 | $0.07 | |
| Oct 18, 2024 | Oct 18 | Nov 8 | $0.07 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 111.56M · Float 102.20M · 91.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 18.26M | 16.37% | 13F | Aug 14, 2026 |
| Jupiter Topco LLC | 8.64M | 7.74% | 13F | Aug 14, 2026 |
| Edgepoint Investment Group Inc. | 8.54M | 7.66% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 7.66M | 6.86% | 13F | Aug 7, 2026 |
| Janus Henderson Group PLC | 7.63M | 6.60% | 13G | Nov 14, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 20, 2026 | Anita Gonzales | officer: Vice President and CAO | −85 | $109.48 |
| Apr 20, 2026 | Anita Gonzales | officer: Vice President and CAO | −80 | $92.80 |
| Feb 24, 2026 | Miriame Victor | officer: Please See Remarks | −1,862 | $97.13 |
| Feb 23, 2026 | Michelle McMurry-Heath | director | −600 | $97.26 |
| Feb 5, 2026 | Joel S. Goldberg | officer: Please See Remarks | −12,717 | $100.21 |
Peers
- Thermo Fisher Scientific
Broad overlap in research tools and specialty diagnostics
- Danaher
Platform overlap across life sciences, diagnostics, and bioprocessing
- Bio-Rad Laboratories
Two-segment peer in life-science research and clinical diagnostics
- Waters
Current owner of former BD biosciences and diagnostic overlap
- QIAGEN
Molecular diagnostics and sample-to-insight workflow peer
- Bio-Techne
Reagents, antibodies, protein analysis, and diagnostics specialist
- Illumina
Sequencing and genomics peer in omics and reproductive health
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Revvity | $127.20 | −1.25% | $14.37B | 61.3 | 22.9 | 4.9 | −1.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Danaher | $215.50 | −0.25% | $151.89B | 38.4 | 24.3 | 6.0 | +5.5% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| Waters | $414.33 | −0.03% | $31.02B | 103.4 | 26.5 | 6.7 | +113.3% |
| QIAGEN | $43.00 | −0.28% | $8.89B | 22.1 | 17.3 | 4.2 | +0.3% |
| Bio-Techne | $72.36 | +0.01% | $11.33B | 62.4 | 34.9 | 9.3 | +1.3% |
| Illumina | $215.70 | +0.02% | $32.62B | 40.2 | 37.6 | 7.3 | +9.4% |
| Median | 40.2 | 26.5 | 6.0 | +5.5% |